Given the critical role of galectins in cancer and other diseases, considerable efforts have been deployed towards the development of carbohydrate-based inhibitors that limit the binding of galectins to glycosylated residues on cell surface receptors. However, despite decades of research, progress in this field has not met expectations. In this article, we discuss the rationale justifying the development of a new class of galectin-specific peptide inhibitors that disrupt the formation of a prototypic galectin and its protumorigenic functions. These dimer interfering peptides (DIPs) represent an interesting alternative-and possibly a complementary avenue-to neutralize galectin-mediated protumoral functions. If validated, the approach could broaden the classes of galectin inhibitors that can be readily generated against other prototypic galectins, and possibly all other galectin subtypes.
A. The Need for New Galectin Inhibitors
Often, these inhibitors are high molecular weight, naturally occurring or chemically-modified plant polysaccharides with significant structural complexity, or small mono/disaccharides that block binding of extracellular galectins to cell surface glycoreceptors (4, 5) .
These include modified citrus pectin (MCP) or GCS-100. In some cases, the effectiveness of this approach in neutralizing the galectin-mediated immune suppression has been demonstrated using in vivo preclinical studies. For example, intratumoral injection of thiodigalactoside (TDG) increases the infiltration of cancer-killing immune cells (6, 7) . However, the effectiveness of plant oligosaccharides and other galectin carbohydrate-based inhibitors in restoring cancer-killing activity of immune cells, such as the synthetic glycoamine analog lactulosyl-L-Leu, remains to be established.
Until now, studies on the anti-tumoral efficacy of these compounds have mostly focused on their ability to inhibit the survival of human cancer cells or their resistance to drug-induced apoptosis (8) (9) (10) . Moreover, these carbohydrate-based inhibitors often have a relatively low binding affinity for galectins and the assumption that many of these drugs are true selective CRD inhibitors has recently been challenged (11) .
Based on the hypothesis that galectin ligand binding avidity is increased during clustering of glycoreceptors, several investigators have thus developed synthetic glycopolymers/glycodendrimers that target the GBS of galectins (12) (13) (14) (15) . Yet, the greatest challenge using GBS inhibitors (GBSIs) is to achieve high selectivity to minimize off-target effects, especially considering the striking structural and GBS similarity between all human galectin CRDs (Fig.   1C ). The use of (glyco) peptides identified following screening of libraries is an interesting avenue that is being explored to identify GBSIs with better selectivity for galectin-1 and -3 (16 (Article for special issue on Galectins) Fig. 1 . Representative homodimeric structure of a prototypic galectin. A) Crystal structure of human galectin-7 showing the 30 kDa 'back-toback' homodimer architecture of the two carbohydrate recognition domains (CRDs) (PDB entry 5GAL). Protomer 1 (gray, on the left) is complexed with disaccharide N-acetyllactosamine (LacNAc, in red), sitting in the glycan binding site (GBS). Residues of the GBS are shown as ball-and-stick representation with standard coloring scheme: red for oxygen, blue for nitrogen, and green for carbon. Protomer 2 (on the right) is unbound and colored by secondary structure: yellow for β-strands, red for α-helix, and green for random coil. B) Side-view of protomer 1 (90° counter clockwise rotation about the y-axis relative to A), seen from the concave side that binds carbohydrate ligands. Each galectin-7 protomer is 15 kDa (135 residues) and forms a β-sandwich secondary structure with two slightly bent β-sheets delineating a convex and a concave side. The boxed area illustrates the glycan binding site (GBS), zoomed on the right. Highly conserved residues involved in hydrogen bonding, hydrophobic, polar, and electrostatic interactions with LacNAc and/or important crystallographic water molecules are shown as ball-and-stick representation. C) Overlay of all structurally resolved monomeric human CRDs from GAL-1, -2, -3, -4, -7, -8, -9, -10, with lactose-bound ligands shown as cyan sticks (PDB entries 1QKQ, 2EAK, 5GAL, 3AP4, 1W6O, 4R9A, 4YM3, and 5DG2). Striking structural similarity between CRDs, analogous ligand positioning in the glycan binding site, and highly conserved GBS residues further illustrate that individual galectin specificity is not exclusively controlled by their carbohydrate binding lectin properties. Galectin function is also mediated by distinct oligomeric architectures and glycan-independent interactions with small-molecule and/or protein partners.
have shown that breast and prostate cancer tissues express multiple galectins that contribute to the heterogeneity of cancer. Using tissue microarrays constructed with biopsies of breast cancer patients, we found that multiple galectins, including GAL-1, -3, -7, -8, and -9, were expressed across all molecular subtypes of breast cancer, except for GAL-7, which was specifically expressed in aggressive Her-2-positive and triple-negative subtypes (17, 18 ). Yet, the field of galectin inhibitors has been largely dominated by studies that almost exclusively focused on GAL-1 and GAL-3. We still have very limited knowledge of the role of other galectins in mediating immune functions, and whether they exhibit pro-or anti-tumoral properties. A good example of such contradictory role for galectins is provided by our data in breast cancer. We have shown that while GAL-1 is associated with cancer progression, GAL-8 has a protective effect (18) . Also, in colon cancer, while GAL-1 and GAL-7 are pro-tumorigenic, GAL-4 acts as a tumor suppressor (19) (20) (21) . Such dual role for galectins in cancer is well documented, especially for GAL-3 and GAL-7 (22) (23) (24) . A better knowledge of the fine specificity contributions of the GBS and the rational design of drugs that take into account these fine specificities may help towards a successful drug development path for GBSIs. Another challenge in the development of galectin inhibitors is that GBSIs are not effective at targeting glycan-independent functions of galectins. As discussed below, accumulating evidence shows that several biological functions of galectins are accomplished through glycan-independent interactions. Consequently, there is an urgent need to go back to the drawing board to refine our strategies for the development of new, effective, and specific galectin inhibitors.
B. Glycan-Independent Functions of Galectins?
For a long time, plant lectins have been known to bind noncarbohydrate and hydrophobic ligands such as peptides, adenine, fluorescent probes, and porphyrins in a glycan-independent fashion, often exhibiting higher affinities than their 'natural' saccharide ligands (26) . Unsurprisingly, the numerous biological functions of galectins can also be accomplished independently of their lectin activity. This has been well documented for intracellular galectin activities. For example, GAL-7 interacts with intracellular BCL-2 family members via a GBS-independent interaction (26, 27) . Similarly, intracellular GAL-3 and -4 directly bind to beta-catenin, a non-glycosylated protein (28, 29) . Additionally, GBS-independent functions of galectins are not limited to their intracellular activities. This is particularly well illustrated during the formation of an immune synapse following the binding of GAL-1 to the surrogate light chain (SLC) of the pre-B cell receptor, whereby GAL-1 is produced by the stromal cells from the bone marrow (pre-BCR) complex expressed on the surface of immature B cells (30) . GAL-1 directly binds to a non-glycosylated form of SLC, indicating a direct protein-protein interaction. A GBS-independent mechanism was also observed during the activation of glial cells by extracellular soluble GAL-3 (31), or activation of human monocytes by GAL-2 (32). Clathrin-mediated endocytosis of GAL-3 by M1 macrophage is also carbohydrate-independent and mediated by its N-terminal domain, as evidenced by its insensitivity to lactose or TDG139, or to mutations that render its GBS ineffective to lactose binding (33) . GAL-3 also binds to bacterial polysaccharides (LPS) via a non-GBS-mechanism (34) . From an evolutionary perspective, such GBS-independent function in galectins may not be so surprising. Many galectin-like proteins in mammals do not exhibit β-galactoside binding activity, including the lens crystallin protein GRIFIN (galectin related inter-fiber protein), which forms a stable homodimer, and the galectin-related protein GRP (previously known as HSPC159; hematopoietic stem cell precursor), which exists as a monomer in solution (35) (36) (37) . In zebrafish and chicken, however, the GRIFIN homolog can bind β-galactosides (38, 39) , suggesting that galectin-like proteins have evolved from ancestral galectins to accommodate a variety of protein-protein interactions with cell surface receptors to modulate intracellular signals.
Our recent findings in prostate cancer showing that alterations in the GBS of GAL-7 shift the balance towards GBS-independent binding partners and drive a phenotypic switch in cancer cells emphasize the importance of GBS-independent galectin activity in cancer (40) . Apart from GAL-3, which mediates protein-protein interactions via its long polypeptide tail, we know very little about how prototypic and/or tandem-repeat galectins mediate GBS-independent interactions. For prototypic galectins, which are typically found in a monomer/homodimer equilibrium in solution, it is logical to hypothesize that GBS-independent interactions may involve residues located at the homodimeric interface. This equilibrium may depend on galectin concentrations within a specific cellular compartment, at least in the case of GAL-7, as suggested by data from a study by Ermakova et al. (41) . Using FPLC gel filtration experiments, the authors showed that lactose-free GAL-7 was mostly found as a homodimer at high (>100 µM) concentrations and as a monomer at lower concentrations. They also found that the binding of lactose shifts this equilibrium towards a more stable homodimer form, a conclusion supported by their circular dichroism-based thermal denaturation studies. Their NMR analysis further showed that GBS occupancy possibly promotes reorientation of residues at the dimer interface. This suggests that occupancy of the GBS with endogenous ligands could potentially impact protein-protein interactions, which in turn may rely on fine specificities of the GBS. This has been shown for GAL-9, a member of the tandem repeat subtype of galectins (42) . For prototypic galectins, comparative structural studies using NMR spectroscopy, isothermal titration calorimetry, and X-ray crystallography of their CRD in the free state and in complex with protein ligands will be needed to provide a detailed understanding of how ligand binding to the GBS affects protein-protein interactions and galectin architecture, and inversely whether such interactions modulate the fine specificities of the GBS. Solving these issues could lead to a paradigm shift in our understanding of galectin function and the development of galectin-specific antagonists.
C. Galectin Oligomerization: an Evolutionary Perspective
Like most proteins belonging to the lectin family, galectins harbor a tertiary structure characterized by a 'jelly roll' fold consisting of anti-parallel β-sheets of approximately 135-140 amino acid residues (Fig. 1) . The 3D structure of each protomeric CRD is similar to the jelly roll CRD found among plant and other ancestral lectins. Ancestral lectin structural organization further suggests that family members have gone through selective pressure for stabilizing a multivalent quaternary structure to increase ligand affinity and/or to promote a distinct biological activity. This occurs either following the association of different mono-or dimeric structures, Fig. 2 . Oligomerization of lectins and galectins through evolution. Lectins and galectins are found in nearly all life forms and exhibit similar jelly roll carbohydrate recognition domains (CRDs), but distinct quaternary structural architecture. The dimeric structure of prototypic human galectins can display 'side-by-side' CRD homodimerization (GAL-1 and GAL-2, PDB entries 3W58 and 5DG2), or 'back-to-back' homodimerization (GAL-7, PDB entry 5GAL). Tetramer formation is often observed in plant and ancestral lectins, with significantly distinct packing architecture. Tetramer architectures are shown for the CchG-1 galectin from Cinachyrella sp. (Ball Sponge, PDB entry 4AGV), the PNA lectin from Arachis hypogaea (Peanut Lectin, PDB entry 1CIW), and concanavalin A from Canavalia ensiformis (Jack Bean, PDB entry 1CJP). Highly conserved residues of the GBS are shown on galectins as ball-and-stick representation with standard coloring scheme: red for oxygen, blue for nitrogen, and yellow for carbon.
or via multiple CRDs encoded within a single polypeptide chain.
Such multivalency is a common feature of lactose-and galactosebinding lectins, which can form tetramers, hexamers, and octamers through a variety of quaternary arrangements and subunit swaps (Fig. 2) (25, 43, 44 (Fig. 2) . This oligomeric architecture for a galectin from an ancestral organism has also been recently described in the case of CGL, a lectin from the sea mussel Crenomytilus grayanus (52). Although we still ignore whether CGL exists as a monomer or oligomer in living organisms, crystal structures revealed a hexameric organization consisting of six CGL protomers. This lectin is structurally close to MytiLec, another recently described lectin with 85% identity to CGL found in the blue mussel, Mytilus galloprovincialis (52, 53) .
What controls the equilibrium between monomeric and oligomeric forms of galectins in living organisms remains poorly understood. Except for GAL-3, which forms oligomers via at least two distinct mechanisms of action (54) , in general, for prototypic galectins, it is believed that this equilibrium is modulated, at least in part, by galectin concentration, although this assumption has been challenged in the case of GAL-1 (55) 
D. Analysis of the Prototypic Galectin Homodimer Interface
Although lectins generally exhibit similar monomeric 3D structures in their CRD, their distinctive quaternary architecture has recently attracted considerable interest due to the biological significance of unique molecular determinants defining their oligomeric organization. This is especially true for prototypic galectins, the major subfamily type found in humans and other species (66) .
In mammals, from the 15 galectins that have been identified to date, 9 are prototypic (GAL-1, -2, -5, -7, -10, -11, -13, -14, and -15). Except for GAL-5, which is exclusively monomeric and has only been found adsorbed on the surface of rat reticulocytes and erythrocytes (67, 68) , prototypic galectins adopt a homodimeric quaternary structure. How lectins form homodimers has been the subject of intense research. In some cases, such as plant lectins, specific signature sequences have been identified to explain the different modes of association implicated in the formation of homodimers (69) . Each human galectin has its own sequence signature, which excludes most of the residues found in the signature sequence of the plant lectin interface. In fact, examination of human GAL-1, GAL-2, and GAL-7 reveals that each has its own homodimerization pattern. While GAL-1 and GAL-2 respectively adopt 'side-by-side' and twisted 'side-by-side' orientations of their CRDs, GAL-7 exhibits a 'back-to-back' CRD homodimerization architecture (Fig. 2) (44) . The homodimeric interface of human GAL-7 is estimated to cover a surface of approximately 1494 Å 2 , as compared to 1093 Å 2 and 1179 Å 2 for GAL-1 and GAL-2, respectively (70) . The larger homodimeric interface of GAL-7 is stabilized by a significant number of electrostatic interactions between symmetrical arginine, lysine, aspartate, and glutamate residues on opposite protomer subunits (Fig. 3A-B) . Protected by these numerous electrostatic interactions, a solvent-shielded hydrophobic core of leucine, isoleucine, valine, and phenylalanine residues lies within this homodimeric interface. The homodimeric interface of other galectins is also stabilized by similar non-bonded interactions. However, since most 'side-by-side' homodimers primarily rely on a smaller number of hydrogen-bonding interactions involving 4 antiparallel β-strands, they may generally be weaker than those observed in the 'back-to-back' dimer orientation of Fig. 3 . Rational design strategy for selecting GAL-7 dimer interfering peptides (DIPs). A) Electrostatic and hydrophobic interactions stabilizing the 'back-to-back' homodimer interface of GAL-7. Polar and charged residues sit above and below the hydrophobic core of the interface.
Residues are shown as ball-and-stick representation with green or yellow carbon coloring for residues from protomer 1 (left) and protomer 2 (right), respectively. B) Side-view of protomer 1 (90° clockwise rotation about the y-axis relative to A), showing individual residues involved in the GAL-7 interface. C) To disrupt the homodimer interface of GAL-7, mimic peptides encompassing residues 13-25 (β-strand S4, red), 86-102 (β-strands S2-S3, green), 95-108 (β-strands S1-S2, blue), and 129-135 (β-strand S5, yellow) were synthesized and tested for their ability to disrupt GAL-7 homodimerization and biological function . Due to sequence overlap between designed peptides 86-102 and 95-108, only β-strand S3 of peptide 86-102 is colored green on the structure. GAL-7. In fact, a single mutation at the extreme N-terminus of GAL-1 is sufficient to alter the monomer-dimer equilibrium (71) .
Naturally, the residues involved are completely distinct from one galectin to the other, and so is the architecture formation of the dimer interface (Fig. 2) . Such differences render them incapable of forming a GAL-7-like interface, further providing an interesting target area to generate inhibitor selectivity via specific signature sequence motifs.
E. Disruption of Galectin-7 Homodimers
As a proof-of-concept for testing whether disruption of the homodimer interface of galectins is a viable strategy for developing effective and selective inhibitors, our group has examined the dimer interface region of human GAL-7, which behaves as a dimer in solution and also crystallizes as a dimer (70, 72, 73) . We focused on GAL-7 because our previous work and that of others showed that it is the only galectin family member with an expression profile restricted to epithelial cells. Abnormally high expression of GAL-7 is also associated with aggressive subtypes of many carcinomas, including breast cancer, for which there are limited therapeutic options. Moreover, we have previously shown that GAL-7 plays a pivotal role in controlling the metastatic behavior of breast Although sequence identity between galectin subtypes is relatively low, monomeric protomers display nearly identical 3D structures and similar binding affinities for glycosidic ligands (see Fig. 1C ). This is represented by yellow, green and blue schematic protein structures that bind an identical glycoside (red triangles). In contrast, quaternary structure is specific to each galectin subtype, exhibiting various back-to-back (BTB) or side-by-side (SBS) homodimeric protein-protein architectures. Synthesis of a glycosidic inhibitor has low chance of success due to non-specific binding to the highly homologous glycan binding sites (GBS) found on all galectin subtypes (red triangles). However, the unique protein-protein interface of each galectin subtype can be rationally targeted by specific designer peptides competing with homodimeric galectin interface formation. In this case, unique molecular interactions involved in GAL-7 homodimerization were targeted by peptides corresponding to individual interface β-strands. Solubility or low affinity peptides can further be improved, namely by PEGylation, peptide mutagenesis, and/or using unnatural amino acid derivatives. Bottom panel: Synthesis of a tight DIP provides specificity against one galectin subtype, uniquely perturbing the proper homodimeric interface and only affecting the biological function of the targeted galectin.
cancer cells (74) . We and others have also reported similar findings for epithelial ovarian cancer (75, 76) , for which there is no effective treatment. The design of a 'dimer interfering peptide' (DIP) strategy was based on the structural and rational analysis of the GAL-7 homodimeric interface, most notably targeting residues that symmetrically associate with their respective partner on the second protomer through H-bonding, electrostatic and/or hydrophobic interactions (Fig. 3A-B) . For GAL-7, DIPs were designed to rationally mimic and disrupt β-strand segments encompassing residues 13-25, 86-102, 95-108, and 129-135, since those residues are directly involved in the stabilization of the homodimeric interface (Fig. 3C) . We rationalized that using these peptides to hinder the interaction with their mirror partner could effectively perturb homodimerization, further affecting the biological function of GAL-7
( 
F. Peptides as Inhibitors of Galectin Homodimers
While the development of DIPs to inhibit galectin homodimers is in its infancy, it can certainly take advantage of the rapidly evolving field of drugs that modulate oligomerization of protein complexes (78) . The potential of targeting the homodimer/heterodimer interface as an effective means to suppress cancer is probably best illustrated by the MDM2/MDMX-p53 case (79) .
MDM2 is an E3 ligase that forms homodimers that bind p53, a well-known tumor-suppressor protein that functions as a transcriptional activator of many pro-apoptotic genes. Binding of MDM2 to p53 enables its E3 ligase activity to transfer ubiquitin to multiple lysine residues of p53, thereby negatively regulating its transcrip- 
G. Conclusions
Dimer interfering peptides (DIPs) represent a new approach for the development of galectin inhibitors. Using a combination of biophysical characterization of the homodimer interface with predictive semi-rational bioinformatics approaches, we can finally envision a new generation of highly specific inhibitors capable of altering both GBS-dependent and -independent functions of pro-totypic galectins. The idea that tandem-repeat galectins can also form higher order aggregates that increase their avidity opens up the possibility of using DIPs for other subtypes of galectins as well [Vasta, 2012] . 
